Bispecific antibodies are the next breakthrough in cancer therapy, but current R&D is limited by a lack of scalable and flexible design platforms. LiliumX overcomes this limitation by using a modular protein platform, rapidly generating and testing thousands of candidate bispecifics using robotic screening and big data analysis to discover bispecific lead assets with entirely new modes of action.
Location: United Kingdom, England, London
Employees: 1-10
Founded date: 2021
Investors 5
| Date | Name | Website |
| - | Y Combinat... | ycombinato... |
| - | Oxford Uni... | innovation... |
| 14.01.2022 | Thomas McI... | tgm.com |
| 08.07.2022 | Creative D... | creativede... |
| - | Magnet Ven... | magnet.ven... |
Mentions in press and media 1
| Date | Title | Description |
| 24.03.2021 | Y Combinator’s biotech startups incubate a new generation of therapies and tools | Medical and biotech had a strong showing at Y Combinator’s latest demo day, with nearly a dozen companies in the space catching my eye. The things a startup can accomplish in this space are astonishing these days, so don’t be surprised if a... |